BPTH — Bio Path Holdings Share News
0.000.00%
Last trade - 00:00Brief: Bio-Path Q1 EPS USD -4.88
Bio Path Holdings Inc expected to post a loss of $4.54 a share - Earnings Preview
Brief: Bio Path Holdings May Offer And Sell Up To $2 Mln Of Common Stock From Time To Time Through Wainwright
Brief: Bio Path Received Deficiency Letter From Nasdaq Notifying Co Is Not In Compliance With Minimum Stockholders' Equity Requirement
Brief: Bio Path Holdings, On March 8, Regained Compliance With Nasdaq's Minimum Bid Price Requirement
Bio Path Holdings Inc expected to post a loss of $5.40 a share - Earnings Preview
Brief: Bio-Path Holdings Announces 1-For-20 Reverse Stock Split
Brief: Bio-Path Holdings Completes First Dose Cohort In Phase 1 Clinical Trial For Blood Cancer Treatment
Brief: Bio-Path Q3 EPS USD -0.32
Brief: Bio Path Holdings Says On Sept 13 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Bio Path Holdings Inc reports results for the quarter ended in June - Earnings Summary
Brief: Bio-Path Q2 EPS USD -0.53
Bio Path Holdings Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Bio-Path Holdings Announces Pricing Of $2.1 Mln Public Offering
Brief: Bio-Path Holdings Announces Positive Results From Interim Analysis Of Phase 2 Clinical Trial Of Prexigebersen In Acute Myeloid Leukemia
Brief: Bio-Path Holdings Announces Successful Completion Of First Dose Cohort In Phase 1/1B Clinical Trial Of Bp1001-A In Solid Tumors
U.S. STOCKS ON THE MOVE-DXP Enterprises, Holley, Augmedix
Bio-Path Holdings falls on wider Q1 loss
Brief: Bio Path Holdings Inc QTRLY Loss Per Share $0.66